จำหน่ายเกจวัดแรงดัน Pressure Gauge ทุกยี่ห้อ

ศูนย์รวมเครื่องมือวัดความดัน

Acquisition will add to Dover’s single-use element providing

Dover has entered into a definitive settlement to acquire Malema Engineering Corp, a US designer and manufacturer of high-precision, mission-critical flow-measurement and control devices for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
ชนิดของpressuregauge will expand Dover’s biopharma single-use production providing, which already includes Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with services in San Jose, California, Singapore, South Korea and India, Malema expects to generate approximately US$40 million–45 million in income in the course of the full yr 2022.
When the deal closes, Malema will turn out to be a half of the PSG business unit within Dover’s Pumps & Process Solutions section.
“We see an incredible long-term progress alternative within the bioprocessing industry pushed by a strong and rising pipeline of effective novel biologic medicine, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, ตัววัดแรงดันน้ำ growing adoption of extra environment friendly single-use production processes supports a strong outlook for our offerings of single-use elements to end-customers. We imagine that pairing Malema’s expertise with our present portfolio of single-use pumps for biopharma processing will tremendously enhance the accuracy and value proposition of our options to our clients.”
“We are methodically constructing out our biopharma platform via proactive capability additions, new product development, and opportunistic acquisitions of highly-attractive area of interest element applied sciences,” stated Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing technology and additional strengthens our sensor portfolio with new proprietary expertise. In addition to engaging biopharma purposes, we anticipate strong development in the semiconductor space on the capacity expansion and re-shoring tailwinds.”
Share